



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/561659/2015

European Medicines Agency decision

P/0218/2015

of 2 October 2015

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for acotiamide (EMEA-001461-PIP02-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0218/2015

of 2 October 2015

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for acotiamide (EMA-001461-PIP02-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Zeria Pharmaceutical Co Ltd on 7 November 2014 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 August 2015, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for acotiamide, coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for acotiamide, coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver acotiamide, coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Zeria Pharmaceutical Co Ltd, Building 3, Chiswick Park, 566 Chiswick High Road, W4 5YA – London, United Kingdom.

Done at London, 2 October 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/367243/2015
London, 14 August 2015

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001461-PIP02-14

Scope of the application

Active substance(s):

Acotiamide

Condition(s):

Treatment of functional dyspepsia

Pharmaceutical form(s):

Coated tablet

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Zeria Pharmaceutical Co Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Zeria Pharmaceutical Co Ltd submitted for agreement to the European Medicines Agency on 7 November 2014 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 16 December 2014.

Supplementary information was provided by the applicant on 20 May 2015. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of functional dyspepsia

The waiver applies to:

- the paediatric population from birth to less than 4 years of age;
- coated tablet, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of functional dyspepsia

2.1.1. Indication(s) targeted by the PIP

Treatment of functional dyspepsia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Coated tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1: Development of an age appropriate oral formulation.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 2 (Z338-05): Randomised, double-blind, placebo-controlled study to evaluate efficacy, safety and tolerability and population pharmacokinetics of acotiamide in children from 9 years to less than 18 years with functional dyspepsia.

Area	Number of measures	Description
		Study 3 (Z338-06): Open label study to evaluate efficacy, safety and tolerability and population pharmacokinetics of acotiamide in children from 4 years to less than 9 years with functional dyspepsia.
Extrapolation, modelling and simulation studies	1	Study 4 (Z338-04): Modelling and simulation study, to evaluate the use of the product and define the dose in the treatment of functional dyspepsia in children from 4 years to less than 18 years of age.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes